Evozym Biologics to co-develop innovative enzymes with GenScript

 Jun 12, 2011

Piscataway, NJ May 2011 -- Genscript USA, Inc, today announced a strategic collaboration and business alliance in synthetic biology with Evozym Biologics, Inc.. The companies intend to develop next generation proteins and enzymes by combining Evozym Biologics innovative enzyme/protein design capabilities with GenScripts gene synthesis and protein expression capabilities. GenScript is a premier CRO and DNA synthesis company, says Joseph Grzymski co-founder and President of Evozym. We are incredibly excited to introduce them to our protein evolution and computational design platforms. We believe our collaboration will allow both companies to leverage strengths and create next generation bio-products efficiently and cost-effectively.

About Genscript USA, Inc.
GenScript USA, Inc., is a leading biology CRO focusing on early drug discovery and development services. Built on assembly-line mode, one-stop solution, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into value chain and operations. GenScript is the largest gene synthesis provider in the U.S. Their customers include top pharmaceutical companies, major biotech firms and research institutions in over 70 countries. www.genscript.com

About Evozym Biologics, Inc.
Evozym Biologics, Inc., is an evolutionary and environmental biology company revolutionizing statistical genomics to exploit new potentials for bioengineered protein design, bioremediation and drug-targeting. Two professors, Joseph J. Grzymski and Adam G. Marsh, with more than 25 years research experience, founded the company. Evozyms proprietary platform technology utilizes evolutionary and environmental biology combined with multi-core computation to bioengineer the evolutionary construction of novel proteins or the deconstruction of existing proteins into their most critical functional components. The unique ability to apply a revolutionary understanding of gene and protein architecture provides a next-generation approach to a suite of genes, proteins and bioprocesses that will change the economic paradigm of discovery and production in multiple biologics-oriented market segments. www.evozym.com

# # # #

For further information, please contact:
Sally Wang
Executive Vice President
GENSCRIPT USA Inc.
sallyw@genscript.com
1-(732) 885-9188

Source: http://www.genscript.com

Your Innovation Partner in Drug Discovery!